The DOI matches its Crossref record; 95 of the 95 references it cites were found in a registry or an index.
mTOR signaling and drug development in cancer
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
Hudes, G., Carducci, M., Tomczak, P., Dutcher, J., Figlin, R., Kapoor, A., Staroslawska, E., Sosman, J., McDermott, D., Bodrogi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066838 · Cited by 3,647
Watterson, K. R., Bestow, D., Gallagher, J., Hamilton, D. L., Ashford, F. B., Meakin, P. J., & Ashford, M. L. J. (2013) · Neurosignals · doi:10.1159/000334144 · Cited by 3,389
Motzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., Grünwald, V., Thompson, J. A., Figlin, R. A., Hollaender, N., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61039-9 · Cited by 3,019
Sarbassov, D. D., Ali, S. M., Kim, D.-H., Guertin, D. A., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2004) · Current Biology · doi:10.1016/j.cub.2004.06.054 · Cited by 2,665
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561
Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB
Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J.-H., Hsu, P. P., Bagley, A. F., Markhard, A. L., & Sabatini, D. M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.029 · Cited by 2,365
Nagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.022 · Cited by 1,858 · cited 1×
“A substantial amount of preclinical data suggest that lack of response to EGFR and HER2-directed therapeutics is associated with deregulation of downstream signaling elements and mTOR activation”
BackgroundRaptor, a Binding Partner of Target of Rapamycin (TOR), Mediates TOR Action
Hara, K., Maruki, Y., Long, X., Yoshino, K.-I., Oshiro, N., Hidayat, S., Tokunaga, C., Avruch, J., & Yonezawa, K. (2002) · Cell · doi:10.1016/s0092-8674(02)00833-4 · Cited by 1,810
Guba, M., von Breitenbuch, P., Steinbauer, M., Koehl, G., Flegel, S., Hornung, M., Bruns, C. J., Zuelke, C., Farkas, S., Anthuber, M., et al. (2002) · Nature Medicine · doi:10.1038/nm0202-128 · Cited by 1,739
(2000) · PubMed · Cited by 1,445
Carracedo, A., Ma, L., Teruya-Feldstein, J., Rojo, F., Salmena, L., Alimonti, A., Egia, A., Sasaki, A. T., Thomas, G., Kozma, S. C., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34739 · Cited by 1,381
The tor pathway: a target for cancer therapy
Bjornsti, M.-A., & Houghton, P. J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1362 · Cited by 1,314
Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis
Bissler, J. J., McCormack, F. X., Young, L. R., Elwing, J. M., Chuck, G., Leonard, J. M., Schmithorst, V. J., Laor, T., Brody, A. S., Bean, J., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa063564 · Cited by 1,253
Hudson, C. C., Liu, M., Chiang, G. G., Otterness, D. M., Loomis, D. C., Kaper, F., Giaccia, A. J., & Abraham, R. T. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.20.7004-7014.2002 · Cited by 1,186
Current development of mTOR inhibitors as anticancer agents
Faivre, S., Kroemer, G., & Raymond, E. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2062 · Cited by 1,000
Atkins, M. B., Hidalgo, M., Stadler, W. M., Logan, T. F., Dutcher, J. P., Hudes, G. R., Park, Y., Liou, S.-H., Marshall, B., Boni, J. P., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.185 · Cited by 942
Shah, O. J., Wang, Z., & Hunter, T. (2004) · Current Biology · doi:10.1016/j.cub.2004.08.026 · Cited by 798
A complex interplay between Akt, TSC2 and the two mTOR complexes
Huang, J., & Manning, B. D. (2009) · Biochemical Society Transactions · doi:10.1042/bst0370217 · Cited by 724
Galanis, E., Buckner, J. C., Maurer, M. J., Kreisberg, J. I., Ballman, K., Boni, J., Peralba, J. M., Jenkins, R. B., Dakhil, S. R., Morton, R. F., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.622 · Cited by 694
Self-citationYao, J. C., Phan, A. T., Chang, D. Z., Wolff, R. A., Hess, K., Gupta, S., Jacobs, C., Mares, J. E., Landgraf, A. N., Rashid, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.7858 · Cited by 649
Hess, G., Herbrecht, R., Romaguera, J., Verhoef, G., Crump, M., Gisselbrecht, C., Laurell, A., Offner, F., Strahs, A., Berkenblit, A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.7977 · Cited by 641
Cloughesy, T. F., Yoshimoto, K., Nghiemphu, P., Brown, K., Dang, J., Zhu, S., Hsueh, T., Chen, Y., Wang, W., Youngkin, D., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050008 · Cited by 593
Targeting phosphoinositide 3-kinase—Moving towards therapy
Marone, R., Cmiljanovic, V., Giese, B., & Wymann, M. P. (2008) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2007.10.003 · Cited by 548
Phase II Trial of Single-Agent Temsirolimus (CCI-779) for Relapsed Mantle Cell Lymphoma
Witzig, T. E., Geyer, S. M., Ghobrial, I., Inwards, D. J., Fonseca, R., Kurtin, P., Ansell, S. M., Luyun, R., Flynn, P. J., Morton, R. F., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.13.466 · Cited by 514
Clinical Pharmacokinetics of Everolimus
Kirchner, G. I., Meier-Wiedenbach, I., & Manns, M. P. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443020-00002 · Cited by 508
Raymond, E., Alexandre, J., Faivre, S., Vera, K., Materman, E., Boni, J., Leister, C., Korth-Bradley, J., Hanauske, A., & Armand, J.-P. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.116 · Cited by 499
O'Donnell, A., Faivre, S., Burris, H. A., Rea, D., Papadimitrakopoulou, V., Shand, N., Lane, H. A., Hazell, K., Zoellner, U., Kovarik, J. M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.0988 · Cited by 479
Tabernero, J., Rojo, F., Calvo, E., Burris, H., Judson, I., Hazell, K., Martinelli, E., Cajal, S. R. Y., Jones, S., Vidal, L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.5482 · Cited by 474
Chan, S., Scheulen, M. E., Johnston, S., Mross, K., Cardoso, F., Dittrich, C., Eiermann, W., Hess, D., Morant, R., Semiglazov, V., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.66.130 · Cited by 468
Rapamycin and mTOR kinase inhibitors
Ballou, L. M., & Lin, R. Z. (2008) · Journal of Chemical Biology · doi:10.1007/s12154-008-0003-5 · Cited by 442
Copp, J., Manning, G., & Hunter, T. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3014 · Cited by 422
Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme
Chang, S. M., Wen, P., Cloughesy, T., Greenberg, H., Schiff, D., Conrad, C., Fink, K., Robins, H. I., De Angelis, L., Raizer, J., et al. (2005) · Investigational New Drugs · doi:10.1007/s10637-005-1444-0 · Cited by 395
Self-citationdeGraffenried, L. A., Friedrichs, W. E., Russell, D. H., Donzis, E. J., Middleton, A. K., Silva, J. M., Roth, R. A., & Hidalgo, M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0035 · Cited by 387
Yu, K., Toral-Barza, L., Shi, C., Zhang, W.-G., Lucas, J., Shor, B., Kim, J., Verheijen, J., Curran, K., Malwitz, D. J., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0299 · Cited by 330
Antiangiogenic Potential of the Mammalian Target of Rapamycin Inhibitor Temsirolimus
Del Bufalo, D., Ciuffreda, L., Trisciuoglio, D., Desideri, M., Cognetti, F., Zupi, G., & Milella, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2825 · Cited by 317
A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas
Duran, I., Kortmansky, J., Singh, D., Hirte, H., Kocha, W., Goss, G., Le, L., Oza, A., Nicklee, T., Ho, J., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603419 · Cited by 317
Self-citationOral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer
Wolpin, B. M., Hezel, A. F., Abrams, T., Blaszkowsky, L. S., Meyerhardt, J. A., Chan, J. A., Enzinger, P. C., Allen, B., Clark, J. W., Ryan, D. P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.9514 · Cited by 297
Salvesen, H. B., Carter, S. L., Mannelqvist, M., Dutt, A., Getz, G., Stefansson, I. M., Raeder, M. B., Sos, M. L., Engelsen, I. B., Trovik, J., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806514106 · Cited by 290
Yee, K. W. L., Zeng, Z., Konopleva, M., Verstovsek, S., Ravandi, F., Ferrajoli, A., Thomas, D., Wierda, W., Apostolidou, E., Albitar, M., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0764 · Cited by 285
Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells.
Grünwald, V., deGraffenried, L. A., Russel, D., Friedrichs, W. E., Ray, R. B., & Hidalgo, M. M. (2002) · PubMed · Cited by 279
Mita, M. M., Mita, A. C., Chu, Q. S., Rowinsky, E. K., Fetterly, G. J., Goldston, M., Patnaik, A., Mathews, L., Ricart, A. D., Mays, T., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.0345 · Cited by 273
Geoerger, B., Kerr, K., Tang, C. B., Fung, K., Powell, B., Sutton, L. N., Phillips∥, P. C., & Janss, A. J. (2001) · PubMed · Cited by 261
Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma
Reardon, D. A., Desjardins, A., Vredenburgh, J. J., Gururangan, S., Friedman, A. H., Herndon, J. E., Marcello, J., Norfleet, J. A., McLendon, R. E., Sampson, J. H., et al. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-9950-0 · Cited by 232
CCI‐779 in metastatic melanoma: A Phase II trial of the California Cancer Consortium
Margolin, K., Longmate, J., Baratta, T., Synold, T., Christensen, S., Weber, J., Gajewski, T., Quirt, I., & Doroshow, J. H. (2005) · Cancer · doi:10.1002/cncr.21265 · Cited by 227
Breuleux, M., Klopfenstein, M., Stephan, C., Doughty, C. A., Barys, L., Maira, S.-M., Kwiatkowski, D., & Lane, H. A. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0668 · Cited by 225
Rizzieri, D. A., Feldman, E., DiPersio, J. F., Gabrail, N., Stock, W., Strair, R., Rivera, V. M., Albitar, M., Bedrosian, C. L., & Giles, F. J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1372 · Cited by 222
Hidalgo, M., Buckner, J. C., Erlichman, C., Pollack, M. S., Boni, J. P., Dukart, G., Marshall, B., Speicher, L., Moore, L., & Rowinsky, E. K. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0118 · Cited by 212
Sirolimus Therapy in Tuberous Sclerosis or Sporadic Lymphangioleiomyomatosis
Davies, D. M., Johnson, S. R., Tattersfield, A. E., Kingswood, J. C., Cox, J. A., McCartney, D. L., Doyle, T., Elmslie, F., Saggar, A., de Vries, P. J., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmc072500 · Cited by 211
Amato, R. J., Jac, J., Giessinger, S., Saxena, S., & Willis, J. P. (2009) · Cancer · doi:10.1002/cncr.24280 · Cited by 201
Lu, C.-H., Wyszomierski, S. L., Tseng, L.-M., Sun, M.-H., Lan, K.-H., Neal, C. L., Mills, G. B., Hortobagyi, G. N., Esteva, F. J., & Yu, D. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2837 · Cited by 200
Neuhaus, P., Klupp, J., & Langrehr, J. M. (2001) · Liver Transplantation · doi:10.1053/jlts.2001.24645 · Cited by 192
Edinger, A. L., Linardic, C. M., Chiang, G. G., Thompson, C. B., & Abraham, R. T. (2003) · PubMed · Cited by 188
Bjornsti, M.-A., & Houghton, P. J. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.05.027 · Cited by 181
A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM)
Kreisl, T. N., Lassman, A. B., Mischel, P. S., Rosen, N., Scher, H. I., Teruya-Feldstein, J., Shaffer, D., Lis, E., & Abrey, L. E. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-008-9741-z · Cited by 176
El-Hashemite, N., Walker, V., Zhang, H., & Kwiatkowski, D. J. (2003) · PubMed · Cited by 167
Patel, P. H., Senico, P. L., Curiel, R. E., & Motzer, R. J. (2009) · Clinical Genitourinary Cancer · doi:10.3816/cgc.2009.n.004 · Cited by 167
Soria, J.-C., Shepherd, F. A., Douillard, J.-Y., Wolf, J., Giaccone, G., Crino, L., Cappuzzo, F., Sharma, S., Gross, S. H., Dimitrijevic, S., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp060 · Cited by 163
Phase I Study of Everolimus in Pediatric Patients With Refractory Solid Tumors
Fouladi, M., Laningham, F., Wu, J., O'Shaughnessy, M. A., Molina, K., Broniscer, A., Spunt, S. L., Luckett, I., Stewart, C. F., Houghton, P. J., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.4017 · Cited by 160
Targeting mTOR with rapamycin: One dose does not fit all
Foster, D. A., & Toschi, A. (2009) · Cell Cycle · doi:10.4161/cc.8.7.8044 · Cited by 159
Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus
Durán, I., Siu, L. L., Oza, A. M., Chung, T., Sturgeon, J. F. G., Townsley, C. A., Pond, G. R., Seymour, L., & Niroumand, M. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.03.015 · Cited by 152
Lasithiotakis, K. G., Sinnberg, T. W., Schittek, B., Flaherty, K. T., Kulms, D., Maczey, E., Garbe, C., & Meier, F. E. (2008) · Journal of Investigative Dermatology · doi:10.1038/jid.2008.44 · Cited by 152
Pandya, K. J., Dahlberg, S. E., Hidalgo, M. M., Cohen, R. B., Lee, M. W., Schiller, J. H., & Johnson, D. H. (2007) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318155a439 · Cited by 148
Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma
Col, J. D., Zancai, P., Terrin, L., Guidoboni, M., Ponzoni, M., Pavan, A., Spina, M., Bergamin, S., Rizzo, S., Tirelli, U., et al. (2008) · Blood · doi:10.1182/blood-2007-07-103481 · Cited by 146
Rapamycin treatment for a child with germline PTEN mutation
Marsh, D. J., Trahair, T. N., Martin, J. L., Chee, W. Y., Walker, J. L., Kirk, E. P., Baxter, R. C., & Marshall, G. M. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1112 · Cited by 143
The Role of mTOR Inhibitors in the Management of Posttransplant Malignancy
Monaco, A. P. (2009) · Transplantation · doi:10.1097/tp.0b013e318193886e · Cited by 134
Angelo, J. C. (2008) · Frontiers in bioscience · doi:10.2741/2925 · Cited by 133
Shor, B., Zhang, W., Toral‐Barza, L., Lucas, J., Abraham, R. T., Gibbons, J. J., & Yu, K. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6487 · Cited by 131
Garcia, J. A., & Danielpour, D. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2408 · Cited by 131
Targeting mTOR in renal cell carcinoma
Hudes, G. R. (2009) · Cancer · doi:10.1002/cncr.24239 · Cited by 117
Manegold, P. C., Paringer, C., Kulka, U., Krimmel, K., Eichhorn, M., Wilkowski, R., Jauch, K., Guba, M. O., & Bruns, C. J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0955 · Cited by 117
Ma, W. W., Jacene, H. A., Song, D., Vilardell, F., Messersmith, W. A., Laheru, D. A., Wahl, R. L., Endres, C., Jimeno, A., Pomper, M. G., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.8383 · Cited by 117
A phase II trial of the mTOR inhibitor AP23573 as a single agent in advanced endometrial cancer
Colombo, N., McMeekin, S., Schwartz, P. E., Kostka, J., Sessa, C., Gehrig, P. A., Holloway, R., Braly, P. S., Matei, D. E., & Einstein, M. H. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.5516 · Cited by 100
Therapeutic targeting of mTOR in tuberous sclerosis
Sampson, J. R. (2009) · Biochemical Society Transactions · doi:10.1042/bst0370259 · Cited by 100
Mammalian target of rapamycin as a therapeutic target in oncology
Abraham, R. T., & Eng, C. H. (2008) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.12.2.209 · Cited by 99
Hartford, C. M., Desai, A. A., Janisch, L. A., Karrison, T. G., Rivera, V. M., Berk, L., Loewy, J. W., Kindler, H. L., Stadler, W. M., Knowles, H., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2076 · Cited by 96
Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors
Carracedo, A., Baselga, J. M., & Pandolfi, P. P. (2008) · Cell Cycle · doi:10.4161/cc.7.24.7244 · Cited by 92
Oza, A. M., Elit, L., Biagi, J. J., Chapman, W., Tsao, M., Hedley, D. W., Hansen, C. P., Dancey, J. E., & Eisenhauer, E. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.3003 · Cited by 89
Self-citationEverolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines
Monica, S. L., Galetti, M., Alfieri, R. R., Cavazzoni, A., Ardizzoni, A., Tiseo, M., Capelletti, M., Goldoni, M., Tagliaferri, S., Mutti, A., et al. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.04.033 · Cited by 88
PI3K/mTORC1 activation in hamartoma syndromes: Therapeutic prospects
Krymskaya, V. P., & Goncharova, E. A. (2009) · Cell Cycle · doi:10.4161/cc.8.3.7555 · Cited by 86
Merchan, J. R., Liu, G., Fitch, T. R., Picus, J., Qin, R., Pitot, H. C., Maples, W. J., & Erlichman, C. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.5034 · Cited by 80
de Aguirre, Boya, P., Bellet, D. H., Faivre, S. J., Troalen, F., Bénard, J., Saulnier, P., Hopkins-Donaldson, S., Zangemeister‐Wittke, U., Kroemer, G., et al. (2004) · APOPTOSIS · doi:10.1023/b:appt.0000045781.46314.e2 · Cited by 78
Optimal targeting of the mTORC1 kinase in human cancer
Lane, H. A., & Breuleux, M. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2009.01.016 · Cited by 76
Chawla, S. P., Tolcher, A. W., Staddon, A. P., Schuetze, S. M., D’Amato, G. Z., Blay, J., Sankhala, K. K., Daly, S. T., Rivera, V. M., & Demetri, G. D. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.9505 · Cited by 74
Patnaik, A., Ricart, A. D., Cooper, J., Papadopoulos, K. P., Beeram, M., Mita, C., Mita, M. M., Hufnagel, D., Izbicka, E., & Tolcher, A. W. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.3512 · Cited by 72
Pharmacokinetics and Safety of Single Oral Doses of Sirolimus (Rapamycin) in Healthy Male Volunteers
m, C. B., we, J. S., Jansson, B., nnebo, A. L., Nordin, J., Zimmerman, J. J., Burke, J. T., & GROTH, C. G. (2000) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200010000-00006 · Cited by 65
Zhong, H., Hanrahan, C. F., van der Poel, H. G., & Simons, J. W. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.4981 · Cited by 56
Oza, A. M., Elit, L., Provencher, D. M., Biagi, J. J., Panasci, L., Sederias, J., Dancey, J. E., Tsao, M., & Eisenhauer, E. A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.5516 · Cited by 53
Self-citationInhibition of mTOR radiosensitizes soft tissue sarcoma and tumor vasculature
Murphy, J. D., Spalding, A. C., Somnay, Y. R., Markwart, S., Ray, M. E., & Hamstra, D. A. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1019 · Cited by 44
Cejka, D., Kuntner, C., Preusser, M., Fritzer-Szekeres, M., Fueger, B. J., Strommer, S., Werzowa, J. M., Fuereder, T., Wanek, T., Zsebedics, M., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605076 · Cited by 39
Merchan, J. R., Pitot, H. C., Qin, R., Liu, G., Fitch, T. R., Picus, J., Maples, W. J., & Erlichman, C. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.5039 · Cited by 39
Activity of single agent temsirolimus (CCI-779) in non-mantle cell non-Hodgkin lymphoma subtypes
Smith, S. M., Pro, B., Cisneros, A., Smith, S. E., Stiff, P. J., Lester, E. P., Modi, S., Dancey, J. E., Vokes, E. E., & van Besien, K. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.8514 · Cited by 33
Self-citationFischer, P., Patel, P., Carducci, M. A., McDermott, D. F., Hudes, G. R., Lubiniecki, G. M., Gelder, M. S., Senico, P., Curiel, R. E., & Motzer, R. J. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.16020 · Cited by 29
Farag, S. S., Zhang, S., Miller, M., Buckner, M., Kraut, E. H., Chan, K., Eng, C., Byrd, J. C., Dancey, J. E., & Grever, M. R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.7616 · Cited by 10
Self-citationMcDaid, H. M., Legrier, M., Yang, C. H., Yan, H. G., Lopez-Barcons, L. A., Keller, S. M., & Horwitz, S. B. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.10615 · Cited by 6
Targeting the IGF-1/mTOR pathway
Houghton, P. J. (2008) · Clinical Cancer Research · Cited by 3
Cited by
Oral Druggable Space beyond the Rule of 5: Insights from Drugs and Clinical Candidates
Doak, B. C., Over, B., Giordanetto, F., & Kihlberg, J. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.08.013 · Cited by 835
PTEN loss in the continuum of common cancers, rare syndromes and mouse models
Hollander, M. C., Blumenthal, G. M., & Dennis, P. A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3037 · Cited by 794
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 720
Overcoming cancer therapeutic bottleneck by drug repurposing
Zhang, Z., Zhou, L., Xie, N., Nice, E. C., Zhang, T., Cui, Y., & Huang, C. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00213-8 · Cited by 516
Cap and cap‐binding proteins in the control of gene expression
Topisirovic, I., Svitkin, Y. V., Sonenberg, N., & Shatkin, A. J. (2011) · WIREs RNA · doi:10.1002/wrna.52 · Cited by 401
Metadata
- Authors
- Dancey, J.
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2010-03-16
- Volume
- 7
- Issue
- 4
- Pages
- 209-219
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- OpenAlex
- W2000110198
- Cited by
- 417
- References
- 95
- FWCI
- 2.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.